Wednesday, June 06, 2012 11:25:46 PM
ref
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=76338403
In my post "(1)" is For the Pharmacological Formulation Patent Grant 8,182,836
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,182,836.PN.&OS=PN/8,182,836&RS=PN/8,182,836
Elaborating further
"(1)The 1st Patent Grant 8,182,836 is for the Pharmacological Formulation of the polymer ( Eudragit 30D/40D)that sequesters and prevents the antagonist from leaking into the body before 3 days."
This Patent Grant assures the correct antagonist delivery when ELI-216 is taken by a patient through the oral ROA as prescribed by the physician. The antagonist will NOT be prematurely leaked and that this feature is expected to be intact for 3 days inside the patient. After 3 days it is expected that the antagonist beads will be passed harmlessly by the patient.
####
"(2)The current 2nd Patent Application 12/640,344 is the 2-bead manufacturing technology that makes (1) work when the agonist opioid and the antagonist opioid are combined and taken together"
This Patent Application 12/640,344 is the unique 2-bead manufacturing technology invented by Elite to assure the correct intact DELIVERY of the agonist and antagonist beads inside the human body. Namely that (i) the agonist CR polymer 12 hrs or 24 hrs releases the opioid correctly time wise as designed and (ii) the antagonist sequestered membrane polymer does not leak prematurely but remains intact unbroken during the 3 days and then passes harmlessly out.
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 10/10/2024 08:47:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/27/2024 08:30:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 09:16:11 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:05:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:07:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 08:30:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:55:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 07:21:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 09:20:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:20:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/28/2023 12:05:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:58:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:50:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration with ZenaDrone • InvestorsHub NewsWire • 11/16/2023 12:32:07 PM
ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • HALO • Oct 10, 2024 8:09 AM
CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products • CBDL • Oct 10, 2024 8:00 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • ELEM • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM